Degussa discovers India

Williams, Debe
April 2006
Chemical Market Reporter;4/3/2006, Vol. 269 Issue 13, p19
Trade Publication
The article analyzes the long-term non-exclusive manufacturing agreement for pharmaceutical intermediates and active pharmaceutical ingredients signed by Germany's Degussa and India's Hikal in early March 2006. The move is part of Degussa's strategy of deriving a double-digit percentage of its sales from production in India. Degussa will gradually move some synthesis of intermediates and lower-margin products to India or China, while work involving higher-value-added products will be kept in Europe.


Related Articles

  • Hikal to Supply APIs for Pfizer in Bangalore. Ramesh, Deepti // Chemical Week;1/7/2008, Vol. 170 Issue 1, p40 

    The article reports on the long-term agreement signed by Hikal Ltd., a manufacturer of active pharmaceutical ingredients (API) and intermediates in Mumbai, India, to contract manufacture and supply API for Pfizer. Hikal will manufacture the API at its U.S. Food and Development Authority...

  • Lynchem key to Degussa's ambitions. Boswell, Clay; Chang, Joseph // ICIS Chemical Business Americas;11/6/2006, Vol. 270 Issue 17, p8 

    The article focuses on the remarks by Joseph Principe, global head of marketing and sales at Degussa, during the Drug, Chemical & Associated Technologies Association/Institute for Supply Management Summit, about the company's choice of joint-venturing over outright purchase. Principe observed...

  • Degussa sets up platform. Beacham, Will // European Chemical News;7/21/2003, Vol. 79 Issue 2062, p6 

    Deals with the Internet-based platform established by Degussa company for pharmaceutical and biopharmaceutical producers looking to outsource services in 2003.

  • Degussa expands capacity in fine chemicals arena.  // Chemical Market Reporter;06/29/98, Vol. 253 Issue 26, p3 

    Reports on Degussa AG's plan to expand its production of pharmaceutical intermediaries and active ingredients by doubling capacity at its Hanau-Wolfgang site in Germany. Focus of the plant's manufacturing process; Main customers for the site's products.

  • Hikal eyes more acquisitions.  // Chemical Business;Jun2005, Vol. 19 Issue 6, p79 

    Reports on the acquisition plans of Hikal Ltd. as of June 2005. Significance of the acquisition to its financial performance; Advantages of its involvement in the pharmaceutical business; Outsourcing deal with a Japanese trading company.

  • Fine Chemical firms Seek Overseas Acquisitions. Scott, Alex // Chemical Week;9/26/2004, Vol. 166 Issue 32, p38 

    Focuses on the business plans of custom pharmaceutical intermediate companies in India. Plans of custom pharmaceutical intermediate companies to acquire U.S.- and European-based companies; Percentage of stake acquired by Hikal in pharmaceutical marketing and distribution firm Marsing & Co.;...

  • HIKAL CHIEF LOOKS AHEAD. Boswell, Clay // ICIS Chemical Business;1/28/2008, Vol. 273 Issue 4, p17 

    The article presents the views of Jai Hiremath, vice chairman and managing director of Mumbai, India-based fine chemical company Hikal Ltd., on the future of India's pharmaceutical manufacturing sector. Hiremath hopes that India will be the heart of pharmaceutical manufacturing. He attributed...

  • pharmaceuticals & fine chemicals.  // Chemical Week;3/9/2005, Vol. 167 Issue 8, p23 

    Presents international news briefs on the pharmaceutical and fine chemical industries as of March 9, 2005. Extension of the a contract between biotechnology firms Lonza and Biotest in Germany for the production of monoclonal antibody BT-061; Plan of agricultural chemicals and pharmaceutical...

  • Gaining Executive Mindshare: Custom Manufacturers.  // Chemical Market Reporter;3/14/2005, Vol. 267 Issue 11, pFR12 

    This article analyses the response of fine chemical companies to the market concerns of big pharma's slower flowing pipelines and the rising influence of offshore producers in India and China. Participating in the roundtable were Rudolf Hanko, vice president, exclusive synthesis at Degussa AG;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics